Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.

Sansure Obtains CE Mark Under IVDR Certification for Surelite Automated CLIA System

Sansure Biotech has achieved a milestone in the field of immunodiagnostics, marking significant progress in international strategic expansion. On the evening of November 14, Sansure Biotech announced that its automated chemiluminescence immunoassay (CLIA) systems recently received the EU CE IVDR certification. The announcement indicates that Surelite 8 and Surelite 16 automated CLIA systems were certified. These systems, along with the […]

Six New Products of Sansure-Controlled Company were Approved Marking a Breakthrough in Chemiluminescence Layout

Sansure Biotech Inc. has made a breakthrough in the field of chemiluminescence immunoassay. Recently, six products independently developed by Accucise Diagnostics Inc., a company controlled by Sansure, obtained medical device registration certificates. These medical device registration certificates were issued by Jiangsu Medical Products Administration (JSMPA). The approved products include the reagents and quality controls of Procalcitonin Detection Kit (Electrochemiluminescence Method) […]

Sansure Announces Investment in Accucise Diagnostics to Lay Out the Field of Immune Diagnosis

On May 9th, Sansure Biotech Inc. issued an investment announcement that jointly establishing Hunan Sansure-Accucise Biotech Co., Ltd. with the Industrial Funds in order to further improve the company’s comprehensive strategic layout in the field of immune diagnosis, especially chemiluminescence. After the establishment of the joint venture company, it will become the investment corpus of Shenzhen Accucise Diagnostics Inc. through […]

Sansure and Singlera Officially Entering the Field of Screening and Early Detection of Cancer Through Their Newly Established Joint Venture

Jiangsu Yang Shengyuan Biotech Co. Ltd., a joint venture, was jointly established by Sansure Biotech and Singlera recently, in which Sansure Biotech holds 40% and Singlera holds 60%. Based on the advantages of its two shareholders, the joint venture will work on livelihood projects in accordance with national policies. In order to contribute to the improvement of the national health […]

Precision detection helps eliminate the Blood Borne Infections

Blood-borne infections are caused by pathogens that are carried in the blood, specifically HBV, HCV and HIV. Germs that can have a long-lasting presence in human blood and other body fluids are called bloodborne pathogens, resulting in organ damages.

1 2 3 9
Get in touch with us
I confirm that I have reviewed Sansure's Privacy Policy and agree with the collection and storage of my personal data.

Thank you!

We shall contact you soon!
Back Top